Reyes-Botero German, Giry Marine, Mokhtari Karima, Labussière Marianne, Idbaih Ahmed, Delattre Jean-Yves, Laigle-Donadey Florence, Sanson Marc
Service de Neurologie 2, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
J Neurooncol. 2014 Jan;116(2):405-11. doi: 10.1007/s11060-013-1312-2. Epub 2013 Nov 17.
Diffuse intrinsic brainstem gliomas (DIBG) account for 1-2 % of adult gliomas. Their biological characteristics are scarcely understood and whether DIBG are biologically different from supratentorial gliomas remains to be established. We analyzed 17 DIBG samples for IDH1 R132H, alpha internexin, p53, and Ki67 expression, and, in a subset with sufficient DNA amount, for IDH1 and histone H3 mutational status, genomic profiling and MGMT promoter methylation status. A series of 738 adult supratentorial gliomas was used for comparison. Median age at diagnosis was 41 years (range 18.9-65.3 years). Median overall survival was 48.7 months (57 months for low-grade vs. 16 months for high-grade gliomas, p < 0.01). IDH1 sequencing revealed two mutations (IDH1 (R132G) , IDH1 (R132C) ) out of 7 DIBG whereas the R132H IDH1 enzyme was detected in 1/17 DIBG, suggesting that IDH1 mutations are mostly non R132H in DIBG (2/2), in contrast to supratentorial gliomas (31/313; p = 0.01). Mutations in histone genes H3F3A (encoding H3.3) and HIST1H3B (encoding H3.1) were found in 3/8 (37.5 %) of the DIBG (two H3F3A (K27M) and one HIST1H3B (K27M) ) versus 6/205 (2.9 %) of the supratentorial high-grade gliomas (four H3F3A (G34R) and two H3F3A (K27M) ) (p = 0.002). The CGH array showed a higher frequency of chromosome arm 1q gain, 9q gain and 11q loss in DIBG compared to the supratentorial high-grade gliomas, which had a less frequent chromosome 7 gain, and a less frequent chromosome 10 loss. No EGFR amplification was found. These data suggest that adult DIBG differ from adult supratentorial gliomas. In particular, histone genes (H3F3A (K27M) , HIST1H3B (K27M) ) mutations are frequent in adult DIBG whereas IDH1 (R132H) mutations are rare.
弥漫性脑桥内在型胶质瘤(DIBG)占成人胶质瘤的1%-2%。其生物学特性鲜为人知,DIBG在生物学上是否与幕上胶质瘤不同仍有待确定。我们分析了17例DIBG样本的异柠檬酸脱氢酶1(IDH1)R132H、α-中间丝蛋白、p53和Ki67表达情况,对于DNA量充足的亚组,还分析了IDH1和组蛋白H3的突变状态、基因组图谱以及O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子甲基化状态。选取738例成人幕上胶质瘤作为对照。诊断时的中位年龄为41岁(范围18.9-65.3岁)。中位总生存期为48.7个月(低级别胶质瘤为57个月,高级别胶质瘤为16个月,p<0.01)。IDH1测序显示,7例DIBG中有2例发生突变(IDH1(R132G)、IDH1(R132C)),而17例DIBG中仅1例检测到R132H IDH1酶,这表明与幕上胶质瘤(31/313;p=0.01)相比,DIBG中的IDH1突变大多不是R132H(2/2)。在3/8(37.5%)的DIBG中发现组蛋白基因H3F3A(编码H3.3)和HIST1H3B(编码H3.1)发生突变(2例H3F3A(K27M)和1例HIST1H3B(K27M)),而幕上高级别胶质瘤中6/205(2.9%)发生突变(4例H3F3A(G34R)和2例H3F3A(K27M))(p=0.002)。比较基因组杂交(CGH)阵列显示,与幕上高级别胶质瘤相比,DIBG中1号染色体长臂增加、9号染色体增加和11号染色体缺失的频率更高,而幕上高级别胶质瘤中7号染色体增加和10号染色体缺失的频率较低。未发现表皮生长因子受体(EGFR)扩增。这些数据表明,成人DIBG与成人幕上胶质瘤不同。特别是,组蛋白基因(H3F3A(K27M)、HIST1H3B(K27M))突变在成人DIBG中很常见,而IDH1(R132H)突变则很少见。